{"id":37976,"date":"2025-08-01T17:33:12","date_gmt":"2025-08-01T17:33:12","guid":{"rendered":"https:\/\/www.newsbeep.com\/au\/37976\/"},"modified":"2025-08-01T17:33:12","modified_gmt":"2025-08-01T17:33:12","slug":"johnson-johnson-stock-analyst-estimates-ratings","status":"publish","type":"post","link":"https:\/\/www.newsbeep.com\/au\/37976\/","title":{"rendered":"Johnson &#038; Johnson Stock: Analyst Estimates &#038; Ratings"},"content":{"rendered":"\n<p class=\"yf-1090901\">New Brunswick, New Jersey-based Johnson &amp; Johnson (JNJ) primarily focuses on drug discovery and manufacturing but has a diversified business model. With a market cap of\u00a0$402.8 billion, Johnson &amp; Johnson operates through\u00a0pharmaceuticals, medical devices, and consumer products divisions.<\/p>\n<p class=\"yf-1090901\">The healthcare giant has notably lagged behind the broader market over the past year but outperformed it in 2025. JNJ stock has\u00a0gained 13.9% on a YTD basis and 2.1% over the past 52 weeks, compared to the S&amp;P 500 Index\u2019s ($SPX)\u00a07.8% gains in 2025 and 16.6% returns over the past year.<\/p>\n<p class=\"yf-1090901\">Narrowing the focus, JNJ has notably outperformed the sector-focused Health Care Select Sector SPDR Fund\u2019s (XLV)\u00a05.2% decline in 2025 and 13.2% drop over the past 52 weeks.<\/p>\n<p>    <img fetchpriority=\"high\" decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"www.barchart.com\" loading=\"eager\" height=\"631\" width=\"960\" class=\"yf-1gfnohs loader\"\/> www.barchart.com      <\/p>\n<p class=\"yf-1090901\">Johnson &amp; Johnson\u2019s stock prices\u00a0surged 6.2% in a single trading session following the release of its\u00a0impressive Q2 results on Jul. 16. Driven by the strength and momentum of its strong product portfolio, the company\u2019s total revenues increased 5.8% year-over-year to $23.7 billion, beating the Street expectations by a notable 3.8%. Meanwhile, its adjusted EPS dipped 1.8% year-over-year to $2.77, but surpassed the consensus estimates by 4.1%, boosting investor confidence.<\/p>\n<p class=\"yf-1090901\">For the full fiscal 2025, ending in December,\u00a0analysts expect an 8.8% year-over-year growth in adjusted EPS to $10.86. Furthermore, the company has a solid earnings surprise history. It has surpassed the Street\u2019s bottom-line estimates in each of the past four quarters.<\/p>\n<p class=\"yf-1090901\">The stock maintains a consensus \u201cModerate Buy\u201d rating overall. Of the 24 analysts covering the stock, opinions include 10 \u201cStrong Buys,\u201d two \u201cModerate Buys,\u201d and 12 \u201cHolds.<\/p>\n<p>    <img decoding=\"async\" src=\"data:image\/gif;base64,R0lGODlhAQABAIAAAAAAAP\/\/\/ywAAAAAAQABAAACAUwAOw==\" alt=\"www.barchart.com\" loading=\"lazy\" height=\"661\" width=\"775\" class=\"yf-1gfnohs loader\"\/> www.barchart.com      <\/p>\n<p class=\"yf-1090901\">This configuration is slightly more bullish than a month ago, when nine analysts gave \u201cStrong Buy\u201d recommendations.<\/p>\n<p class=\"yf-1090901\">On Jul. 17, Guggenheim analyst Vamil Divan maintained a \u201cNeutral\u201d rating on JNJ and raised the price target from $164 to $167.<\/p>\n<p class=\"yf-1090901\">As of writing, JNJ\u2019s mean price target of $175.18 represents a modest 6.3% upside potential. Meanwhile, the Street-high target of $190 suggests a notable 15.3% premium to current price levels.<\/p>\n<p class=\"yf-1090901\"> On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally\u00a0published on <a href=\"https:\/\/www.barchart.com\/story\/news\/33804665\/johnson-johnson-stock-analyst-estimates-ratings?utm_source=yahoo&amp;utm_medium=syndication&amp;utm_content=footer_link\" rel=\"nofollow noopener\" target=\"_blank\" data-ylk=\"slk:Barchart.com;elm:context_link;itc:0;sec:content-canvas\" class=\"link \">Barchart.com<\/a> <\/p>\n","protected":false},"excerpt":{"rendered":"New Brunswick, New Jersey-based Johnson &amp; Johnson (JNJ) primarily focuses on drug discovery and manufacturing but has a&hellip;\n","protected":false},"author":2,"featured_media":37977,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[34],"tags":[64,63,137,500,34167,34166],"class_list":["post-37976","post","type-post","status-publish","format-standard","has-post-thumbnail","category-healthcare","tag-au","tag-australia","tag-health","tag-healthcare","tag-jnj-stock","tag-johnson-johnson"],"_links":{"self":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/37976","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/comments?post=37976"}],"version-history":[{"count":0,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/posts\/37976\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media\/37977"}],"wp:attachment":[{"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/media?parent=37976"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/categories?post=37976"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.newsbeep.com\/au\/wp-json\/wp\/v2\/tags?post=37976"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}